Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors

Author(s): Markus D. Lacher, Maurizio Provenzano

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 8 , Issue 3 , 2013

Become EABM
Become Reviewer


Solid tumors contain several different types of malignant cells. This cellular heterogeneity complicates therapy for at least two reasons. First, each subpopulation may respond differently to a given treatment. Second, cancer cells are plastic, and thus may convert from a therapy-sensitive to a therapy-resistant cell type represented by another subpopulation. Therefore, successful therapies will have to target numerous malignant cell types, not just the rapidly proliferating cells as most standard treatments do. Immunotherapies with T cells engineered to recognize cancer cells via bispecific antibodies (bsAbs) or chimeric antigen receptors (CARs) are particularly promising approaches with potential to ablate both dividing and non/slow-dividing subpopulations of cancer cells. Here, we discuss several patents associated with exceptionally effective bsAbs of the tandem single-chain variable fragment (taFv) class and untangle a part of the complex network of patents directly or indirectly related to CARs. Furthermore, we speculate on the future of bsAbs and CARs for both treatment and prevention of solid tumors such as prostate cancer.

Keywords: Antibody, BiTE, bispecific, cancer, CAR, scFv, taFv.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [239 - 254]
Pages: 16
DOI: 10.2174/15748928113088880003
Price: $65

Article Metrics

PDF: 82